Response to: Letter to the Editor Regarding Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM.
- DOI
- 10.1007/s12325-022-02328-6
- Published
- 2022-10-19
- Container
- Adv Ther
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s12325-022-02328-6,
title = {Response to: Letter to the Editor Regarding Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM.},
author = {Kawaguchi Y and Hajika Y and Ashida N and Masumoto K and Sawa J and Hamazaki K and Kumeda Y.},
year = {2023},
journal = {Adv Ther},
doi = {10.1007/s12325-022-02328-6},
url = {https://doi.org/10.1007/s12325-022-02328-6}
}RIS
TY - JOUR TI - Response to: Letter to the Editor Regarding Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM. AU - Kawaguchi Y AU - Hajika Y AU - Ashida N AU - Masumoto K AU - Sawa J AU - Hamazaki K AU - Kumeda Y. PY - 2023 JO - Adv Ther DO - 10.1007/s12325-022-02328-6 UR - https://doi.org/10.1007/s12325-022-02328-6 ER -
APA
Y, K., Y, H., N, A., K, M., J, S., K, H., & Y., K. (2023). Response to: Letter to the Editor Regarding Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM.. Adv Ther. https://doi.org/10.1007/s12325-022-02328-6
Source records
- europe-pmc · retrieved 2026-09-26T01:26:33.819Z